Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia.
The combination of Ethyldeshydroxy-Sparsomycin (EdSm) with cisdiamminedichloroplatinum(II) (CDDP) caused significant antitumour activity against murine L1210 leukemia. Although single drug treatment by cisplatin generated some cures, all schedules of combined treatment, using nontoxic doses of EdSm (5mg/kg) and cisplatin (3 mg/kg), resulted in the cure of 4 to 6 mice in each group consisting of 6 mice. No differences in antitumour activity were observed between pretreatment, simultaneous treatment or posttreatment of cisplatin with EdSm. Increasing the number of tumour cells implanted i.p. diminished the antitumour effect of both EdSm as well as CDDP, but not for the drug combination. Changing the route of administration from i.p. to i.v. for one of the drugs out of the combination resulted in loss of antitumour activity.
Hofs
H P
HP
Department of Internal Medicine, Nijmegen University Hospital, The Netherlands.
Wagener
D J
DJ
De Valk-Bakker
V
V
Van Rennes
H
H
Van Zeist
A J
AJ
Van Den Broek
L A
LA
Ottenheijm
H C
HC
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D004357:Drug Synergism; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D009368:Neoplasm Transplantation; D013033:Sparsomycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C074101:ethyldeshydroxysparsomycin; D013033:Sparsomycin; D002945:Cisplatin